New diabetes clinical trial: Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?
Published on: April 09, 2025 at 11:00PM
Conditions: Type 1 Diabetes (T1D)
Interventions: Drug: Dapagliflozin (DAPA); Drug: Pioglitazone 45 mg; Drug: Placebo
Sponsors: Dasman Diabetes Institute
Not yet recruiting
https://ift.tt/oCRXews
Conditions: Type 1 Diabetes (T1D)
Interventions: Drug: Dapagliflozin (DAPA); Drug: Pioglitazone 45 mg; Drug: Placebo
Sponsors: Dasman Diabetes Institute
Not yet recruiting
https://ift.tt/oCRXews
Comments
Post a Comment